Because of the increase in prostate cancer patients, urologists can detect more clinically localized prostate cancer in patients before the disease has progressed to advanced stages. Nevertheless, some patients are still diagnosed with high-risk prostate cancer. Even though several treatment options are available for high-risk prostate cancer patients, including radical prostatectomy, radiotherapy, and hormone therapy, used alone or in combination, the recurrence rate is high regardless of the type of treatment. Nevertheless, in the experience of many urologists, a substantial proportion of high-risk prostate cancer patients are cured by local definite therapy or multimodality treatment. Thus, several treatment combinations have been attemp...
<p>Patients with high-risk prostate cancer (PC) make up a heterogeneous population who has a substan...
Despite the wide application of prostate-specific antigen-based screening leading to a profound stag...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Because of the increase in prostate cancer patients, urologists can detect more clinically localized...
Because of the increase in prostate cancer patients, urologists can detect more clinically localized...
AbstractHigh risk prostate cancer is a deadly disease that needs aggressive treatment. High risk pro...
In this review, the role of surgery in patients with adverse tumor characteristics and a high risk o...
Although the optimal treatment for patients with high-risk prostate cancer remains unclear, combined...
Introduction. High-risk prostate cancer represents a therapeutic challenge. The role of radical pros...
High-risk prostate cancer (PCa), which is defined as PSA >20 ng/mL or Gleason Score (GS) >7 or ≥cT3...
High-risk prostate cancer (HR Pca) is a highly heterogeneous disease from a biological and clinical ...
• The optimal management of high-risk localised prostate cancer is a major challenge for urologists ...
<p>Prostate cancer (PC) is one of the most burning problems of modern urologic oncology. Patients at...
We assessed the outcomes of high-risk prostate cancer patients who received radical prostatectomy (R...
Treatment of men with high-risk prostate cancer (PCa) remains challenging for urologists. The comple...
<p>Patients with high-risk prostate cancer (PC) make up a heterogeneous population who has a substan...
Despite the wide application of prostate-specific antigen-based screening leading to a profound stag...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Because of the increase in prostate cancer patients, urologists can detect more clinically localized...
Because of the increase in prostate cancer patients, urologists can detect more clinically localized...
AbstractHigh risk prostate cancer is a deadly disease that needs aggressive treatment. High risk pro...
In this review, the role of surgery in patients with adverse tumor characteristics and a high risk o...
Although the optimal treatment for patients with high-risk prostate cancer remains unclear, combined...
Introduction. High-risk prostate cancer represents a therapeutic challenge. The role of radical pros...
High-risk prostate cancer (PCa), which is defined as PSA >20 ng/mL or Gleason Score (GS) >7 or ≥cT3...
High-risk prostate cancer (HR Pca) is a highly heterogeneous disease from a biological and clinical ...
• The optimal management of high-risk localised prostate cancer is a major challenge for urologists ...
<p>Prostate cancer (PC) is one of the most burning problems of modern urologic oncology. Patients at...
We assessed the outcomes of high-risk prostate cancer patients who received radical prostatectomy (R...
Treatment of men with high-risk prostate cancer (PCa) remains challenging for urologists. The comple...
<p>Patients with high-risk prostate cancer (PC) make up a heterogeneous population who has a substan...
Despite the wide application of prostate-specific antigen-based screening leading to a profound stag...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...